NASDAQ: YDESYd Biopharma Ltd Stock
$17.19-0.42 (-2.39%)
Updated Oct 24, 2025
YDES Price
$17.19
Fair Value Price
$2.01
Market Cap
$1.20B
52 Week Low
$5.30
52 Week High
$31.00
P/E
N/A
P/B
182.84x
P/S
91.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$510.36k
Earnings
-$1.41M
Gross Margin
30.4%
Operating Margin
-271.52%
Profit Margin
-276.6%
Debt to Equity
0.04
Operating Cash Flow
-$2M
Beta
0.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
YDES Overview
Breeze Holdings Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, stock purchases, recapitalizations, reorganizations, or related business combinations. It targets businesses in the energy sector in North America. Breeze Holdings was incorporated in 2020 and is based in Irving, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine YDES's potential to beat the market
- YDES doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
YDES
RankedUnranked of 486
RankedUnranked of 486
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.28 | A | |
| $11.89 | A | |
| $7.20 | A |
Be the first to know about important YDES news, forecast changes, insider trades & much more!
YDES News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how YDES scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YDES ($17.19) is overvalued by 754.16% relative to our estimate of its Fair Value price of $2.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
YDES ($17.19) is not significantly undervalued (754.16%) relative to our estimate of its Fair Value price of $2.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
YDES is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more YDES due diligence checks available for Premium users.
Valuation
YDES fair value
Fair Value of YDES stock based on Discounted Cash Flow (DCF)
Price
$17.19
Fair Value
$2.01
Overvalued by
754.16%
YDES ($17.19) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
YDES ($17.19) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
YDES price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-88.22x
Market
39.01x
YDES price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
182.84x
Industry
4.92x
YDES is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
YDES's financial health
Profit margin
Revenue
$510.4k
Net Income
$1.3M
Profit Margin
256.9%
YDES's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
YDES's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.9M
Liabilities
$274.0k
Debt to equity
0.04
YDES's short-term assets ($3.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YDES's short-term assets ($3.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YDES's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$593.0k
Investing
-$5.8M
Financing
$9.4M
YDES's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
YDES vs Biotech Stocks
Yd Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.